Boyoung Hwang1, Debra K Moser, Michele M Pelter, Thomas S Nesbitt, Kathleen Dracup. 1. From the College of Nursing & Research Institute of Nursing Science (Hwang), Seoul National University, Seoul, Korea; College of Nursing (Moser), University of Kentucky, Lexington, Kentucky; School of Nursing (Pelter, Dracup), University of California, San Francisco, San Francisco, California; and School of Medicine (Nesbitt), University of California, Davis, Sacramento, California.
Abstract
OBJECTIVES: Depression is an independent predictor of adverse outcomes in patients with heart failure (HF). However, the effect of changes in cognitive-affective and somatic symptoms on mortality of HF patients is not known. The purpose of this study was to examine whether changes in cognitive-affective and somatic depressive symptoms over time were associated with mortality in HF. METHODS: In this secondary analysis of data from the Rural Education to Improve Outcomes in Heart Failure clinical trial, we analyzed data from 457 HF patients (39% female, mean [standard deviation] age = 65.6 [12.8] years) who survived at least 1 year and repeated the Patient Health Questionnaire at 1 year. Cognitive-affective and somatic depression scores were calculated, respectively, based on published Patient Health Questionnaire factor models. Using Cox proportional hazards regression analyses, we evaluated the effect of changes in cognitive-affective and somatic symptoms from baseline to 1 year on cardiac and all-cause deaths. RESULTS: Controlling for baseline depression scores and other patient characteristics, the change in somatic symptoms was associated with increased risk of cardiac death during the subsequent 1-year period (hazard ratio = 1.24, 95% confidence interval = 1.07-1.44, p = .005), but the change in cognitive-affective symptoms was not (hazard ratio = 0.94, 95% confidence interval = 0.81-1.08, p = .38). Similar results were found for all-cause mortality. CONCLUSIONS: Worsening somatic depressive symptoms, not cognitive-affective symptoms, are independently associated with increased mortality of HF patients. The findings suggest that routine and ongoing assessment of somatic depressive symptoms in HF patients may help clinicians identify patients at increased risk for adverse outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00415545.
OBJECTIVES:Depression is an independent predictor of adverse outcomes in patients with heart failure (HF). However, the effect of changes in cognitive-affective and somatic symptoms on mortality of HF patients is not known. The purpose of this study was to examine whether changes in cognitive-affective and somatic depressive symptoms over time were associated with mortality in HF. METHODS: In this secondary analysis of data from the Rural Education to Improve Outcomes in Heart Failure clinical trial, we analyzed data from 457 HF patients (39% female, mean [standard deviation] age = 65.6 [12.8] years) who survived at least 1 year and repeated the Patient Health Questionnaire at 1 year. Cognitive-affective and somatic depression scores were calculated, respectively, based on published Patient Health Questionnaire factor models. Using Cox proportional hazards regression analyses, we evaluated the effect of changes in cognitive-affective and somatic symptoms from baseline to 1 year on cardiac and all-cause deaths. RESULTS: Controlling for baseline depression scores and other patient characteristics, the change in somatic symptoms was associated with increased risk of cardiac death during the subsequent 1-year period (hazard ratio = 1.24, 95% confidence interval = 1.07-1.44, p = .005), but the change in cognitive-affective symptoms was not (hazard ratio = 0.94, 95% confidence interval = 0.81-1.08, p = .38). Similar results were found for all-cause mortality. CONCLUSIONS: Worsening somatic depressive symptoms, not cognitive-affective symptoms, are independently associated with increased mortality of HF patients. The findings suggest that routine and ongoing assessment of somatic depressive symptoms in HF patients may help clinicians identify patients at increased risk for adverse outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00415545.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Peter Johansson; Ivonne Lesman-Leegte; Johan Lundgren; Hans L Hillege; Arno Hoes; Robbert Sanderman; Dirk J van Veldhuisen; Tiny Jaarsma Journal: J Psychosom Res Date: 2012-10-23 Impact factor: 3.006
Authors: W Jiang; J Alexander; E Christopher; M Kuchibhatla; L H Gaulden; M S Cuffe; M A Blazing; C Davenport; R M Califf; R R Krishnan; C M O'Connor Journal: Arch Intern Med Date: 2001 Aug 13-27
Authors: Kathleen Dracup; Debra K Moser; Michele M Pelter; Thomas S Nesbitt; Jeffrey Southard; Steven M Paul; Susan Robinson; Lawton S Cooper Journal: Circulation Date: 2014-05-09 Impact factor: 29.690
Authors: Jeffrey S Gonzalez; Naomi S Kane; Deborah H Binko; Amit Shapira; Claire J Hoogendoorn Journal: Diabetes Care Date: 2016-10-17 Impact factor: 19.112
Authors: Kenneth E Freedland; Michael J Hesseler; Robert M Carney; Brian C Steinmeyer; Judith A Skala; Victor G Dávila-Román; Michael W Rich Journal: Psychosom Med Date: 2016-10 Impact factor: 4.312
Authors: Paul J Mills; Pam R Taub; Ottar Lunde; Meredith A Pung; Kathleen Wilson; Christopher Pruitt; Thomas Rutledge; Alan Maisel; Barry H Greenberg Journal: Clin Cardiol Date: 2019-04-29 Impact factor: 2.882